Amneal Just Bet $1.1 Billion That Making Biosimilars Is the Real Gold Rush

Amneal is essentially buying years' worth of headaches, learning curves, and FDA inspections in one transaction.

The $300 Billion Wave Nobody Can Ignore

The timing matters enormously. Over the next decade, more than $300 billion worth of branded biologics will lose patent exclusivity. That's the biggest wave of biosimilar opportunity the industry has ever seen, and companies are scrambling to position themselves before it crests.

Amneal currently has five FDA-approved biosimilars on the U.S. market, including Fylnetra (a copy of Amgen's blockbuster Neulasta) and Releuko (a Neupogen biosimilar). With the Kashiv acquisition, the company expects to have six commercial biosimilars by 2027, including a copy of Xolair (omalizumab), which represents a market opportunity exceeding $4 billion annually. The goal is three to five new biosimilar launches every year after that.

Scaling Up, Fast

One of the most telling details in the deal: Amneal plans to spend $30 to $50 million annually on capital expenditures to nearly triple its drug substance capacity. The target is going from 26,000 liters in 2026 to 75,000 liters by 2028, with flexibility to bolt on another 25,000 liters after that.

That kind of aggressive scaling tells you everything about how Amneal views the competitive landscape. In biosimilars, being second to market with a cheaper drug still works. But being fifth or sixth? The margins get thin fast. Manufacturing muscle lets you launch quickly and supply reliably, two advantages that matter more than shaving another percentage point off the price.

The Family Connection

There's a wrinkle worth noting. Amneal's co-CEOs, Chirag and Chintu Patel, are co-founders of Kashiv. The two companies have been partners since 2017, collaborating on biosimilar development and commercialization. So this isn't exactly a cold call between strangers.

Chintu Patel described the acquisition as establishing Amneal as a "global biosimilar leader" capable of "multiple launches each year." The deal essentially formalizes a relationship that's been deepening for nearly a decade. It also eliminates the milestone payments and royalties Amneal would otherwise owe Kashiv on future products, generating $400 to $500 million in cumulative synergies over time.

Everyone Wants a Factory

Amneal isn't the only company making this bet. In late 2025, Celltrion acquired an Eli Lilly manufacturing facility in the U.S. for $330 million to secure domestic production capacity. Around the same time, Sandoz paid roughly $350 million (plus over $300 million in milestones) for Just-Evotec Biologics' EU facility and its continuous manufacturing technology.

The pattern is clear: biosimilar companies are treating manufacturing sites like strategic weapons. The contract manufacturing market for biosimilars is growing at nearly 14% annually. When demand outstrips supply, owning your own capacity isn't just convenient. It's a competitive moat.

The Big Picture

The U.S. biosimilar market is still in its adolescence. IQVIA projects U.S. biosimilar spending could reach $20 to $49 billion by 2027, a staggering range that reflects both the opportunity and the uncertainty. The U.S. biosimilar market is expected to grow at a 17.5% annual clip through 2034.

For Amneal, which built its reputation as a generic drug company, the Kashiv deal represents a fundamental identity shift. Generics are a volume game with razor-thin margins. Biosimilars are a complexity game with fatter margins but much higher barriers to entry. You need the science, the regulatory expertise, and (crucially) the manufacturing infrastructure.

With this acquisition, Amneal is betting it can be one of the few companies that controls the entire value chain: from developing the biosimilar in the lab, to growing it in bioreactors, to filling vials, to selling it to hospitals. That vertical integration is rare, and if the $300 billion patent cliff plays out as expected, it could be extraordinarily valuable.

The biosimilar gold rush is on. Amneal just bought the pickaxes.